<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="7" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font6" size="8" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font7" size="8" family="GillSans,BoldItalic" color="#000000"/>
	<fontspec id="font8" size="8" family="GillSans" color="#000000"/>
	<fontspec id="font9" size="6" family="GillSans" color="#000000"/>
	<fontspec id="font10" size="8" family="SymbolMT" color="#000000"/>
<text top="41" left="55" width="132" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">BMC Nuclear Medicine 2007, 7 :3<i>BMC Nuclear Medicine</i></text>
<text top="41" left="373" width="181" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://www.biomedcentral.com/1471-2385/7/3</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t3" reading_order_no="184" segment_no="8" tag_type="text">Page 5 of 9<b>7</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="185" segment_no="9" tag_type="text">(page number not for citation purposes)</text>
<text top="310" left="55" width="241" height="9" font="font4" id="p1_t5" reading_order_no="114" segment_no="4" tag_type="text">asymptomatic HIV-positive patients treated with FLT over</text>
<text top="322" left="55" width="241" height="9" font="font4" id="p1_t6" reading_order_no="115" segment_no="4" tag_type="text">a period of 16 weeks. These patients received a de-escalat-</text>
<text top="333" left="55" width="241" height="11" font="font4" id="p1_t7" reading_order_no="116" segment_no="4" tag_type="text">ing oral dose of FLT starting from 0.125 mg/Kg (AUC 12 ~<i>(page number not for citation purposes)</i></text>
<text top="345" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="117" segment_no="4" tag_type="text">417 ng*h/mL) every 12 hours to reach a target area under</text>
<text top="357" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="118" segment_no="4" tag_type="text">the curve of 300 ng*h/mL for a 12 hour dosing interval</text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="119" segment_no="4" tag_type="text">[17]. Serious grade III hematologic toxicity (anemia and</text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="120" segment_no="4" tag_type="text">leukopenia) was observed with concentrations greater</text>
<text top="392" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="121" segment_no="4" tag_type="text">than 300 ng*h/mL. Grade II+ anemia was observed</text>
<text top="404" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="122" segment_no="4" tag_type="text">within 4 weeks with a concentration of 300 ng*h/mL.</text>
<text top="416" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="123" segment_no="4" tag_type="text">Subsequently, a randomized, double-blind phase I/II trial</text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="124" segment_no="4" tag_type="text">was designed to characterize FLT pharmacokinetics, anti-<a href="">[17]. Seriou</a>s grade III hematologic toxicity (anemia and</text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="125" segment_no="4" tag_type="text">viral activity, and toxicity. Forty-eight patients were rand-</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="126" segment_no="4" tag_type="text">omized into 3 groups with different target areas of FLT</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t18" reading_order_no="127" segment_no="4" tag_type="text">concentration (50 ng*h/mL, 100 ng*h/mL, or 200 ng*h/</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="128" segment_no="4" tag_type="text">mL) for up to 16 weeks of treatment. Grade II+ anemia</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="129" segment_no="4" tag_type="text">developed at doses greater than 100 ng*h/mL, granulocy-</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="130" segment_no="4" tag_type="text">topenia at doses greater than 200 ng*h/mL, and mild</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="131" segment_no="4" tag_type="text">peripheral neuropathy within 40 days at any dose. The</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="132" segment_no="4" tag_type="text">bone marrow toxicity was reversible when the drug was</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t24" reading_order_no="133" segment_no="4" tag_type="text">discontinued. This type of toxicity was not seen with</text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="134" segment_no="4" tag_type="text">reduced FLT doses. However, this phase I/II trial was sus-</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="135" segment_no="4" tag_type="text">pended because two patients died from acute hepatic fail-</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t27" reading_order_no="136" segment_no="4" tag_type="text">ure after 12 weeks of therapy, one in Flexner's study at</text>
<text top="580" left="55" width="241" height="11" font="font4" id="p1_t28" reading_order_no="137" segment_no="4" tag_type="text">AUC 12 of 200 ng*h/mL, the other from a European trial</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="138" segment_no="4" tag_type="text">using a 10 mg/day regimen. Therefore, the FLT toxicology</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t30" reading_order_no="139" segment_no="4" tag_type="text">data reported for human therapeutic use shows the lowest</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t31" reading_order_no="140" segment_no="4" tag_type="text">toxicity regimen tested to be 50 ng*h/mL for a 12 hour</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t32" reading_order_no="141" segment_no="4" tag_type="text">dosing interval which led to only mild peripheral neurop-</text>
<text top="639" left="55" width="241" height="9" font="font4" id="p1_t33" reading_order_no="142" segment_no="4" tag_type="text">athy within a mean of 40 days of therapy [17]. Therefore,</text>
<text top="651" left="55" width="241" height="9" font="font4" id="p1_t34" reading_order_no="143" segment_no="4" tag_type="text">in addition to discussing our toxicology data for a single</text>
<text top="662" left="55" width="241" height="9" font="font4" id="p1_t35" reading_order_no="144" segment_no="4" tag_type="text">radiotracer dose of 18 F-FLT, we will compare this dose</text>
<text top="674" left="55" width="241" height="9" font="font4" id="p1_t36" reading_order_no="145" segment_no="4" tag_type="text">level to the multiple larger doses used in this lowest toxic-</text>
<text top="686" left="55" width="83" height="9" font="font4" id="p1_t37" reading_order_no="146" segment_no="4" tag_type="text">ity clinical regimen.</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t38" reading_order_no="147" segment_no="7" tag_type="text">We evaluated the toxicity of 18 F-FLT in a series of 20</text>
<text top="721" left="55" width="241" height="9" font="font4" id="p1_t39" reading_order_no="148" segment_no="7" tag_type="text">patients who underwent 18 F-FLT PET imaging. We took</text>
<text top="310" left="313" width="241" height="9" font="font4" id="p1_t40" reading_order_no="149" segment_no="5" tag_type="text">two different approaches to this evaluation: first, a direct<a href="">[17</a>]. Therefore,</text>
<text top="322" left="313" width="241" height="9" font="font4" id="p1_t41" reading_order_no="150" segment_no="5" tag_type="text">laboratory measure of electrolytes, hepatic, metabolic,</text>
<text top="333" left="313" width="241" height="9" font="font4" id="p1_t42" reading_order_no="151" segment_no="5" tag_type="text">and renal function of these patients; second, a compari-</text>
<text top="345" left="313" width="241" height="9" font="font4" id="p1_t43" reading_order_no="152" segment_no="5" tag_type="text">son of the maximal amount of FLT compound injected for</text>
<text top="356" left="313" width="241" height="10" font="font4" id="p1_t44" reading_order_no="153" segment_no="5" tag_type="text">a 18 F-FLT PET study to the therapeutic dose shown to be</text>
<text top="369" left="313" width="241" height="10" font="font4" id="p1_t45" reading_order_no="154" segment_no="5" tag_type="text">the least toxic in clinical trials. To this end, AUC 12 values</text>
<text top="380" left="313" width="241" height="9" font="font4" id="p1_t46" reading_order_no="155" segment_no="5" tag_type="text">for our study patients were calculated from both imaging-</text>
<text top="392" left="313" width="168" height="9" font="font4" id="p1_t47" reading_order_no="156" segment_no="5" tag_type="text">derived TACs and actual blood samples.</text>
<text top="416" left="313" width="241" height="9" font="font4" id="p1_t48" reading_order_no="157" segment_no="6" tag_type="text">No change was found in the renal function (BUN and cre-</text>
<text top="427" left="313" width="241" height="9" font="font4" id="p1_t49" reading_order_no="158" segment_no="6" tag_type="text">atinine levels) of the 20 patients studied or in the follow-</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t50" reading_order_no="159" segment_no="6" tag_type="text">ing hepatic function measures: AST, ALT, alkaline</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t51" reading_order_no="160" segment_no="6" tag_type="text">phosphatase, and total bilirubin. As described in the</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t52" reading_order_no="161" segment_no="6" tag_type="text">results section, decreases in the patients' average hemat-</text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t53" reading_order_no="162" segment_no="6" tag_type="text">ocrit, RBC and hemoglobin levels were observed. One of</text>
<text top="486" left="313" width="241" height="9" font="font4" id="p1_t54" reading_order_no="163" segment_no="6" tag_type="text">the challenges of this study is that it was designed as a</text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t55" reading_order_no="164" segment_no="6" tag_type="text">companion analysis to a primary imaging study per-</text>
<text top="510" left="313" width="241" height="9" font="font4" id="p1_t56" reading_order_no="165" segment_no="6" tag_type="text">formed in potentially resectable NSCLC. As a result, sev-</text>
<text top="521" left="313" width="241" height="9" font="font4" id="p1_t57" reading_order_no="166" segment_no="6" tag_type="text">enteen of 20 (85%) patients studied underwent surgical</text>
<text top="533" left="313" width="241" height="9" font="font4" id="p1_t58" reading_order_no="167" segment_no="6" tag_type="text">staging (mediastinoscopy and/or video assisted thoracos-</text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t59" reading_order_no="168" segment_no="6" tag_type="text">copy) with 14/20 also undergoing a tumor resection pro-</text>
<text top="557" left="313" width="241" height="9" font="font4" id="p1_t60" reading_order_no="169" segment_no="6" tag_type="text">cedure, at the same time as the mediastinoscopy, under</text>
<text top="568" left="313" width="241" height="9" font="font4" id="p1_t61" reading_order_no="170" segment_no="6" tag_type="text">general anaesthesia after 18 F-FLT PET. Thirteen of the 14</text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t62" reading_order_no="171" segment_no="6" tag_type="text">(93%) had resection within 1 week of the 18 F-FLT PET</text>
<text top="591" left="313" width="241" height="10" font="font4" id="p1_t63" reading_order_no="172" segment_no="6" tag_type="text">study, 7 of these were the day after the 18 F-FLT PET study.</text>
<text top="604" left="313" width="241" height="9" font="font4" id="p1_t64" reading_order_no="173" segment_no="6" tag_type="text">Because surgery involves blood loss and metabolic stress,</text>
<text top="615" left="313" width="241" height="9" font="font4" id="p1_t65" reading_order_no="174" segment_no="6" tag_type="text">hematological values were consequently affected and a</text>
<text top="627" left="313" width="241" height="9" font="font4" id="p1_t66" reading_order_no="175" segment_no="6" tag_type="text">long-term relationship between the 18 F-FLT PET study and</text>
<text top="639" left="313" width="241" height="9" font="font4" id="p1_t67" reading_order_no="176" segment_no="6" tag_type="text">hematological values is difficult to establish. Nonetheless,</text>
<text top="651" left="313" width="241" height="9" font="font4" id="p1_t68" reading_order_no="177" segment_no="6" tag_type="text">when we only consider pre-surgical lab values and all lab</text>
<text top="662" left="313" width="241" height="9" font="font4" id="p1_t69" reading_order_no="178" segment_no="6" tag_type="text">values for patients who did not undergo any surgical pro-</text>
<text top="674" left="313" width="241" height="9" font="font4" id="p1_t70" reading_order_no="179" segment_no="6" tag_type="text">cedure, analysis of the data reveals a single small early</text>
<text top="686" left="313" width="241" height="9" font="font4" id="p1_t71" reading_order_no="180" segment_no="6" tag_type="text">drop in hemoglobin, hematocrit and RBC. This suggests</text>
<text top="698" left="313" width="241" height="9" font="font4" id="p1_t72" reading_order_no="181" segment_no="6" tag_type="text">that the additional drop observed in these parameters at</text>
<text top="709" left="313" width="241" height="9" font="font4" id="p1_t73" reading_order_no="182" segment_no="6" tag_type="text">later time points for the whole population is due to surgi-</text>
<text top="721" left="313" width="241" height="9" font="font4" id="p1_t74" reading_order_no="183" segment_no="6" tag_type="text">cal blood loss. The initial decrease in hemoglobin, hema-</text>
<text top="87" left="55" width="490" height="7" font="font6" id="p1_t75" reading_order_no="2" segment_no="2" tag_type="title">Table 2: Laboratory values (mean ± SD) of the 20 patients at each time point and corresponding one-way Anova P values across all</text>
<text top="96" left="55" width="45" height="7" font="font6" id="p1_t76" reading_order_no="3" segment_no="2" tag_type="title">time points.</text>
<text top="114" left="191" width="32" height="7" font="font6" id="p1_t77" reading_order_no="4" segment_no="3" tag_type="table">Pre-FLT</text>
<text top="114" left="249" width="61" height="7" font="font6" id="p1_t78" reading_order_no="5" segment_no="3" tag_type="table">Immediate &lt;5 h</text>
<text top="114" left="329" width="48" height="7" font="font6" id="p1_t79" reading_order_no="6" segment_no="3" tag_type="table">5 – 24 Hours</text>
<text top="114" left="400" width="37" height="7" font="font6" id="p1_t80" reading_order_no="7" segment_no="3" tag_type="table">1 – 7 days</text>
<text top="114" left="464" width="34" height="7" font="font6" id="p1_t81" reading_order_no="8" segment_no="3" tag_type="table">&gt; 1 week</text>
<text top="114" left="531" width="5" height="7" font="font7" id="p1_t82" reading_order_no="9" segment_no="3" tag_type="table">P</text>
<text top="137" left="88" width="85" height="7" font="font6" id="p1_t83" reading_order_no="10" segment_no="3" tag_type="table">Sodium (mEq/L ± SD)</text>
<text top="137" left="189" width="38" height="7" font="font8" id="p1_t84" reading_order_no="11" segment_no="3" tag_type="table">139.4 ± 1.5</text>
<text top="137" left="261" width="38" height="7" font="font8" id="p1_t85" reading_order_no="12" segment_no="3" tag_type="table">138.2 ± 2.1</text>
<text top="137" left="335" width="38" height="7" font="font8" id="p1_t86" reading_order_no="13" segment_no="3" tag_type="table">138.3 ± 2.0</text>
<text top="137" left="399" width="38" height="7" font="font8" id="p1_t87" reading_order_no="14" segment_no="3" tag_type="table">137.5 ± 1.8</text>
<text top="137" left="462" width="38" height="7" font="font8" id="p1_t88" reading_order_no="15" segment_no="3" tag_type="table">138.1 ± 2.3</text>
<text top="137" left="524" width="18" height="7" font="font8" id="p1_t89" reading_order_no="16" segment_no="3" tag_type="table">0.064</text>
<text top="147" left="77" width="95" height="7" font="font6" id="p1_t90" reading_order_no="17" segment_no="3" tag_type="table">Potassium (mEq/L ± SD)</text>
<text top="147" left="193" width="29" height="7" font="font8" id="p1_t91" reading_order_no="18" segment_no="3" tag_type="table">4.2 ± 0.5</text>
<text top="147" left="265" width="29" height="7" font="font8" id="p1_t92" reading_order_no="19" segment_no="3" tag_type="table">4.2 ± 0.4</text>
<text top="147" left="339" width="29" height="7" font="font8" id="p1_t93" reading_order_no="20" segment_no="3" tag_type="table">4.1 ± 0.4</text>
<text top="147" left="403" width="29" height="7" font="font8" id="p1_t94" reading_order_no="21" segment_no="3" tag_type="table">4.2 ± 0.3</text>
<text top="147" left="466" width="30" height="7" font="font8" id="p1_t95" reading_order_no="22" segment_no="3" tag_type="table">4.2 ± 0.4</text>
<text top="147" left="524" width="18" height="7" font="font8" id="p1_t96" reading_order_no="23" segment_no="3" tag_type="table">0.968</text>
<text top="157" left="84" width="88" height="7" font="font6" id="p1_t97" reading_order_no="24" segment_no="3" tag_type="table">Chloride (mEq/L ± SD)</text>
<text top="157" left="189" width="38" height="7" font="font8" id="p1_t98" reading_order_no="25" segment_no="3" tag_type="table">102.3 ± 3.3</text>
<text top="157" left="261" width="38" height="7" font="font8" id="p1_t99" reading_order_no="26" segment_no="3" tag_type="table">104.2 ± 3.7</text>
<text top="157" left="338" width="32" height="7" font="font8" id="p1_t100" reading_order_no="27" segment_no="3" tag_type="table">104 ± 3.8<b>Table 2: Laboratory values (mean ± SD) of the 20 patients at each time point and corresponding one-way Anova </b></text>
<text top="157" left="399" width="38" height="7" font="font8" id="p1_t101" reading_order_no="28" segment_no="3" tag_type="table">102.3 ± 2.4<i><b>P </b></i></text>
<text top="157" left="462" width="38" height="7" font="font8" id="p1_t102" reading_order_no="29" segment_no="3" tag_type="table">101.2 ± 3.1<b>values across all </b></text>
<text top="157" left="524" width="18" height="7" font="font8" id="p1_t103" reading_order_no="30" segment_no="3" tag_type="table">0.055<b>time points.</b></text>
<text top="167" left="87" width="85" height="7" font="font6" id="p1_t104" reading_order_no="31" segment_no="3" tag_type="table">Glucose (mg/dL ± SD)<b>Pre-FLT</b></text>
<text top="167" left="189" width="38" height="7" font="font8" id="p1_t105" reading_order_no="32" segment_no="3" tag_type="table">95.1 ± 14.8<b>Immediate &lt;5 h</b></text>
<text top="167" left="261" width="38" height="7" font="font8" id="p1_t106" reading_order_no="33" segment_no="3" tag_type="table">96.6 ± 20.7<b>5 – 24 Hours</b></text>
<text top="167" left="335" width="38" height="7" font="font8" id="p1_t107" reading_order_no="34" segment_no="3" tag_type="table">98.5 ± 23.1<b>1 – 7 days</b></text>
<text top="167" left="397" width="42" height="7" font="font8" id="p1_t108" reading_order_no="35" segment_no="3" tag_type="table">105.4 ± 17.7<b>&gt; 1 week</b></text>
<text top="167" left="460" width="42" height="7" font="font8" id="p1_t109" reading_order_no="36" segment_no="3" tag_type="table">109.5 ± 14.6<i><b>P</b></i></text>
<text top="167" left="524" width="18" height="7" font="font8" id="p1_t110" reading_order_no="37" segment_no="3" tag_type="table">0.175<b>Sodium (mEq/L ± SD)</b></text>
<text top="178" left="77" width="95" height="7" font="font6" id="p1_t111" reading_order_no="38" segment_no="3" tag_type="table">Creatinine (mg/dL ± SD)</text>
<text top="178" left="185" width="46" height="7" font="font8" id="p1_t112" reading_order_no="39" segment_no="3" tag_type="table">0.885 ± 0.198</text>
<text top="178" left="257" width="46" height="7" font="font8" id="p1_t113" reading_order_no="40" segment_no="3" tag_type="table">0.882 ± 0.207</text>
<text top="178" left="330" width="46" height="7" font="font8" id="p1_t114" reading_order_no="41" segment_no="3" tag_type="table">0.881 ± 0.180</text>
<text top="178" left="395" width="46" height="7" font="font8" id="p1_t115" reading_order_no="42" segment_no="3" tag_type="table">0.910 ± 0.190</text>
<text top="178" left="458" width="46" height="7" font="font8" id="p1_t116" reading_order_no="43" segment_no="3" tag_type="table">0.844 ± 0.217</text>
<text top="178" left="524" width="18" height="7" font="font8" id="p1_t117" reading_order_no="44" segment_no="3" tag_type="table">0.949<b>Potassium (mEq/L ± SD)</b></text>
<text top="188" left="98" width="74" height="7" font="font6" id="p1_t118" reading_order_no="45" segment_no="3" tag_type="table">BUN (mg/dL ± SD)</text>
<text top="188" left="191" width="34" height="7" font="font8" id="p1_t119" reading_order_no="46" segment_no="3" tag_type="table">15.8 ± 5.0</text>
<text top="188" left="263" width="34" height="7" font="font8" id="p1_t120" reading_order_no="47" segment_no="3" tag_type="table">15.1 ± 5.6</text>
<text top="188" left="337" width="34" height="7" font="font8" id="p1_t121" reading_order_no="48" segment_no="3" tag_type="table">15.2 ± 6.3</text>
<text top="188" left="401" width="34" height="7" font="font8" id="p1_t122" reading_order_no="49" segment_no="3" tag_type="table">14.3 ± 5.2</text>
<text top="188" left="464" width="34" height="7" font="font8" id="p1_t123" reading_order_no="50" segment_no="3" tag_type="table">15.3 ± 5.7</text>
<text top="188" left="524" width="18" height="7" font="font8" id="p1_t124" reading_order_no="51" segment_no="3" tag_type="table">0.959<b>Chloride (mEq/L ± SD)</b></text>
<text top="198" left="104" width="69" height="7" font="font6" id="p1_t125" reading_order_no="52" segment_no="3" tag_type="table">SGOT (U/L ± SD)</text>
<text top="198" left="191" width="34" height="7" font="font8" id="p1_t126" reading_order_no="53" segment_no="3" tag_type="table">20.8 ± 5.0</text>
<text top="198" left="263" width="34" height="7" font="font8" id="p1_t127" reading_order_no="54" segment_no="3" tag_type="table">22.0 ± 5.1</text>
<text top="198" left="337" width="34" height="7" font="font8" id="p1_t128" reading_order_no="55" segment_no="3" tag_type="table">22.0 ± 5.3</text>
<text top="198" left="399" width="38" height="7" font="font8" id="p1_t129" reading_order_no="56" segment_no="3" tag_type="table">22.2 ± 11.4</text>
<text top="198" left="464" width="34" height="7" font="font8" id="p1_t130" reading_order_no="57" segment_no="3" tag_type="table">21.8 ± 6.7</text>
<text top="198" left="524" width="18" height="7" font="font8" id="p1_t131" reading_order_no="58" segment_no="3" tag_type="table">0.973<b>Glucose (mg/dL ± SD)</b></text>
<text top="208" left="105" width="67" height="7" font="font6" id="p1_t132" reading_order_no="59" segment_no="3" tag_type="table">SGPT (U/L ± SD)</text>
<text top="208" left="191" width="34" height="7" font="font8" id="p1_t133" reading_order_no="60" segment_no="3" tag_type="table">18.7 ± 6.7</text>
<text top="208" left="263" width="34" height="7" font="font8" id="p1_t134" reading_order_no="61" segment_no="3" tag_type="table">18.5 ± 6.6</text>
<text top="208" left="337" width="34" height="7" font="font8" id="p1_t135" reading_order_no="62" segment_no="3" tag_type="table">19.1 ± 6.5</text>
<text top="208" left="401" width="34" height="7" font="font8" id="p1_t136" reading_order_no="63" segment_no="3" tag_type="table">17.6 ± 5.3</text>
<text top="208" left="464" width="34" height="7" font="font8" id="p1_t137" reading_order_no="64" segment_no="3" tag_type="table">17.2 ± 6.5</text>
<text top="208" left="524" width="18" height="7" font="font8" id="p1_t138" reading_order_no="65" segment_no="3" tag_type="table">0.978<b>Creatinine (mg/dL ± SD)</b></text>
<text top="219" left="93" width="79" height="7" font="font6" id="p1_t139" reading_order_no="66" segment_no="3" tag_type="table">Albumin (g/dL ± SD)</text>
<text top="219" left="193" width="29" height="7" font="font8" id="p1_t140" reading_order_no="67" segment_no="3" tag_type="table">3.9 ± 0.5</text>
<text top="219" left="265" width="29" height="7" font="font8" id="p1_t141" reading_order_no="68" segment_no="3" tag_type="table">3.5 ± 0.4</text>
<text top="219" left="337" width="34" height="7" font="font8" id="p1_t142" reading_order_no="69" segment_no="3" tag_type="table">3.44 ± 0.3</text>
<text top="219" left="403" width="29" height="7" font="font8" id="p1_t143" reading_order_no="70" segment_no="3" tag_type="table">3.1 ± 0.6</text>
<text top="219" left="466" width="29" height="7" font="font8" id="p1_t144" reading_order_no="71" segment_no="3" tag_type="table">3.2 ± 0.8</text>
<text top="219" left="524" width="18" height="7" font="font8" id="p1_t145" reading_order_no="72" segment_no="3" tag_type="table">0.003<b>BUN (mg/dL ± SD)</b></text>
<text top="229" left="94" width="78" height="7" font="font6" id="p1_t146" reading_order_no="73" segment_no="3" tag_type="table">Alk Phos (U/L ± SD)</text>
<text top="229" left="189" width="38" height="7" font="font8" id="p1_t147" reading_order_no="74" segment_no="3" tag_type="table">73.8 ± 19.4</text>
<text top="229" left="261" width="38" height="7" font="font8" id="p1_t148" reading_order_no="75" segment_no="3" tag_type="table">61.1 ± 14.7</text>
<text top="229" left="335" width="38" height="7" font="font8" id="p1_t149" reading_order_no="76" segment_no="3" tag_type="table">58.3 ± 17.0</text>
<text top="229" left="399" width="38" height="7" font="font8" id="p1_t150" reading_order_no="77" segment_no="3" tag_type="table">59.5 ± 22.7</text>
<text top="229" left="524" width="18" height="7" font="font8" id="p1_t151" reading_order_no="78" segment_no="3" tag_type="table">0.081</text>
<text top="239" left="85" width="87" height="7" font="font6" id="p1_t152" reading_order_no="79" segment_no="3" tag_type="table">Bilirubin (mg/dL ± SD)<b>SGOT (U/L ± SD)</b></text>
<text top="239" left="185" width="46" height="7" font="font8" id="p1_t153" reading_order_no="80" segment_no="3" tag_type="table">0.647 ± 0.181</text>
<text top="239" left="257" width="46" height="7" font="font8" id="p1_t154" reading_order_no="81" segment_no="3" tag_type="table">0.573 ± 0.246</text>
<text top="239" left="330" width="46" height="7" font="font8" id="p1_t155" reading_order_no="82" segment_no="3" tag_type="table">0.581 ± 0.263</text>
<text top="239" left="395" width="46" height="7" font="font8" id="p1_t156" reading_order_no="83" segment_no="3" tag_type="table">0.621 ± 0.286</text>
<text top="239" left="458" width="46" height="7" font="font8" id="p1_t157" reading_order_no="84" segment_no="3" tag_type="table">0.752 ± 0.418</text>
<text top="239" left="524" width="18" height="7" font="font8" id="p1_t158" reading_order_no="85" segment_no="3" tag_type="table">0.714</text>
<text top="247" left="96" width="76" height="10" font="font6" id="p1_t159" reading_order_no="86" segment_no="3" tag_type="table">RBC (x10 6 / μ L ± SD)<b>SGPT (U/L ± SD)</b></text>
<text top="249" left="193" width="29" height="7" font="font8" id="p1_t160" reading_order_no="87" segment_no="3" tag_type="table">4.5 ± 0.4</text>
<text top="249" left="265" width="29" height="7" font="font8" id="p1_t161" reading_order_no="88" segment_no="3" tag_type="table">4.3 ± 0.5</text>
<text top="249" left="339" width="29" height="7" font="font8" id="p1_t162" reading_order_no="89" segment_no="3" tag_type="table">4.2 ± 0.5</text>
<text top="249" left="403" width="29" height="7" font="font8" id="p1_t163" reading_order_no="90" segment_no="3" tag_type="table">3.8 ± 0.3</text>
<text top="249" left="466" width="30" height="7" font="font8" id="p1_t164" reading_order_no="91" segment_no="3" tag_type="table">3.7 ± 0.4</text>
<text top="249" left="519" width="27" height="7" font="font8" id="p1_t165" reading_order_no="92" segment_no="3" tag_type="table">&lt;0.0001</text>
<text top="260" left="91" width="81" height="7" font="font6" id="p1_t166" reading_order_no="93" segment_no="3" tag_type="table">Hematocrit (% ± SD)<b>Albumin (g/dL ± SD)</b></text>
<text top="260" left="191" width="34" height="7" font="font8" id="p1_t167" reading_order_no="94" segment_no="3" tag_type="table">40.9 ± 3.1</text>
<text top="260" left="263" width="34" height="7" font="font8" id="p1_t168" reading_order_no="95" segment_no="3" tag_type="table">39.1 ± 4.4</text>
<text top="260" left="337" width="34" height="7" font="font8" id="p1_t169" reading_order_no="96" segment_no="3" tag_type="table">38.4 ± 4.0</text>
<text top="260" left="401" width="34" height="7" font="font8" id="p1_t170" reading_order_no="97" segment_no="3" tag_type="table">35.2 ± 3.4</text>
<text top="260" left="464" width="34" height="7" font="font8" id="p1_t171" reading_order_no="98" segment_no="3" tag_type="table">35.0 ± 3.4</text>
<text top="260" left="519" width="27" height="7" font="font8" id="p1_t172" reading_order_no="99" segment_no="3" tag_type="table">&lt;0.0001</text>
<text top="267" left="92" width="80" height="10" font="font6" id="p1_t173" reading_order_no="100" segment_no="3" tag_type="table">WBC (x10 3 / μ L ± SD)<b>Alk Phos (U/L ± SD)</b></text>
<text top="270" left="193" width="29" height="7" font="font8" id="p1_t174" reading_order_no="101" segment_no="3" tag_type="table">7.6 ± 2.1</text>
<text top="270" left="265" width="29" height="7" font="font8" id="p1_t175" reading_order_no="102" segment_no="3" tag_type="table">7.7 ± 3.4</text>
<text top="270" left="339" width="29" height="7" font="font8" id="p1_t176" reading_order_no="103" segment_no="3" tag_type="table">7.9 ± 3.3</text>
<text top="270" left="403" width="29" height="7" font="font8" id="p1_t177" reading_order_no="104" segment_no="3" tag_type="table">9.5 ± 2.8</text>
<text top="270" left="466" width="30" height="7" font="font8" id="p1_t178" reading_order_no="105" segment_no="3" tag_type="table">9.0 ± 3.2</text>
<text top="270" left="524" width="18" height="7" font="font8" id="p1_t179" reading_order_no="106" segment_no="3" tag_type="table">0.262<b>Bilirubin (mg/dL ± SD)</b></text>
<text top="278" left="80" width="92" height="10" font="font6" id="p1_t180" reading_order_no="107" segment_no="3" tag_type="table">Platelets (x10 3 / μ L ± SD)</text>
<text top="280" left="187" width="42" height="7" font="font8" id="p1_t181" reading_order_no="108" segment_no="3" tag_type="table">278.1 ± 96.8</text>
<text top="280" left="257" width="46" height="7" font="font8" id="p1_t182" reading_order_no="109" segment_no="3" tag_type="table">259.1 ± 103.1</text>
<text top="280" left="330" width="46" height="7" font="font8" id="p1_t183" reading_order_no="110" segment_no="3" tag_type="table">255.9 ± 103.0</text>
<text top="280" left="397" width="42" height="7" font="font8" id="p1_t184" reading_order_no="111" segment_no="3" tag_type="table">230.1 ± 76.7</text>
<text top="280" left="460" width="42" height="7" font="font8" id="p1_t185" reading_order_no="112" segment_no="3" tag_type="table">233.5 ± 69.5</text>
<text top="280" left="524" width="18" height="7" font="font8" id="p1_t186" reading_order_no="113" segment_no="3" tag_type="table">0.674<b>RBC (x10</b></text>
</page>
</pdf2xml>
